To date, several trials have employed mTOR inhibitors in thyroid cancer (Table 3), whereas the phase II MATCH studies are testing PI3K (e.g., taselisib, copanlisib) and AKT-inhibitors (e.g., capivasertib) (Figure 6). The gene discussed is PIK3CA; the disease is thyroid cancer.